Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices
Open Access
- 15 April 2018
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 93 (6), 816-823
- https://doi.org/10.1002/ajh.25092
Abstract
In patients with immune thrombocytopenia who do not adequately respond to first‐line therapy, there is no clear consensus on which second‐line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long‐term use (e.g. corticosteroids) and overuse of off‐label therapies (e.g. rituximab) while approved, more efficacious options exist. These approaches may not only fail to address symptoms and burden of disease, but may also worsen health‐related quality of life. A better understanding of available second‐line treatments may ensure best use of therapeutic options and thereby optimize patient outcomes.Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 57 references indexed in Scilit:
- Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopeniaBlood, 2013
- Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)British Journal of Haematology, 2012
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- Patient-reported treatment burden of chronic immune thrombocytopenia therapiesBMC Blood Disorders, 2012
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trialsBritish Journal of Haematology, 2009
- Is splenectomy still the gold standard for the treatment of chronic ITP?American Journal of Hematology, 2007
- Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpuraAmerican Journal of Hematology, 2007
- New thrombopoietic growth factorsBlood, 2007
- Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome.Archives of Disease in Childhood, 1995